Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of CNTO 136 in rheumatoid arthritis
2007-006603-20Phase 2Completed
- Sponsor
- Janssen Biotech
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of siltuximab in rheumatoid arthritis (RA), sponsored by Janssen Biotech. Primary endpoint: ACR50 response at Week 12 in Part B. Started May 2009; status: completed.
02
Drugs
siltuximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2007-006603-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-006603-20.